Presentation at The Lancet Summit on GeNeuro’s Novel anti-HERV-K Antibody for Amyotrophic lateral sclerosis
Geneva, Switzerland, December 20, 2021 – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that its Chief Scientific Officer, Dr. Hervé Perron, unveiled today at the “The Lancet Summit: Presymptomatic Prevention and Treatment of Neurodegenerative Diseases” additional results from the preclinical research program in Amyotrophic lateral […]
GeNeuro receives CHF 6.7 million (EUR 6.4 million) in funding from the Swiss government for the development of temelimab against Long-COVID
Geneva, Switzerland, 13 December 2021, 08:15 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, with final Phase II results in multiple sclerosis expected in March 2022, announced today that its development in Long-COVID is one of the four projects selected by the Swiss Federal Office […]
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study
MS Journal, July 9, 2021 https://geneuro.ch/data/news/MSJ-July-21-Efficacy-and-safety-of-temelimab-in-multiple-sclerosis.pdf
Presentation at American Neurological Association Congress Confirms Potential of GeNeuro’s Novel anti-HERV-K Antibody for Amyotrophic lateral sclerosis
Geneva, Switzerland, 18 October, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that the NINDS, part of the U.S. National Institutes of Health (NIH), presented novel pre-clinical results at the American Neurological Association (ANA) annual meeting, October 17-19, confirming in […]
GeNeuro Reports 2021 Half-Year Results and Provides Corporate Update
Geneva, Switzerland, September 29, 2021 at 7:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported its half-year financial results for the period ending June 30, 2021 and provided a corporate update. https://geneuro.ch/data/news/GeNeuro-PR-1H2021-Results-ENG-vf.pdf
GeNeuro and Northwestern University enter into a research collaboration on HERV-W ENV in long-haul COVID
Geneva, Switzerland, September 24, 2021, 8:00am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis, announces today that it has entered into a research agreement with Northwestern University to further investigate the relationship between HERV-W ENV (W-ENV) and long-COVID neuropsychiatric syndromes. https://geneuro.ch/data/news/2021.09.24-GN-PR-NW-agreement-ENG.pdf
GeNeuro announces that a first patient having finished the ProTEct-MS study at the Karolinska Institutet’s Academic Specialist Center has entered the study extension
Geneva, Switzerland, September 21, 2021 – 6:30 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that a first patient having completed its ProTEct-MS study at Karolinska Institutet’s Academic Specialist Center (ASC) in […]
GeNeuro: financial information and business update for the second quarter 2021
Geneva, Switzerland, July 23, 2021, 8:00am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported on its 2021 second quarter cash position and issued a business update. https://geneuro.ch/data/news/GeNeuro-PR-Q2-2021-EN-VF.pdf
GeNeuro announces the publication in Multiple Sclerosis of results from CHANGE-MS and ANGEL-MS studies
Geneva, Switzerland, July 15, 2021 – 08:00am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical developing new treatments for neurodegenerative diseases, such as multiple sclerosis (MS), today announced publication in Multiple Sclerosis of the safety and efficacy results from its temelimab CHANGE-MS and ANGEL-MS clinical studies. https://geneuro.ch/data/news/GeNeuro-PR-MSJournal-publication-EN.pdf
GeNeuro: successful €6 million private placement
Geneva, Switzerland, July 13, 2021 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (“MS”), today announced the successful completion of a €6.0 million capital increase with cancellation of the preferential subscription […]